Operating Profit Turns Positive at KRW 28.7 Billion
Reflecting Sevydopylenib Upfront Payment and Lazertinib Milestone Revenue
R&D Expenses Reach KRW 15.1 Billion, Up 20.6% Year-on-Year

OscoTech reported a significant improvement in business performance in the first half of this year, driven by the upfront payment from the Sevydopylenib technology transfer agreement and milestone and royalty income from Lazertinib.


According to a public disclosure on August 14, OscoTech recorded consolidated sales of KRW 56,296,750,000 and operating profit of KRW 28,682,280,000 in the first half of this year. Sales increased by 371% compared to the same period last year, and operating profit turned positive.

Oschotech company logo image. Oschotech

Oschotech company logo image. Oschotech

View original image

Revenue from the new drug development segment accounted for 97.3% of the total. Of the USD 25 million upfront payment for the technology transfer agreement signed last June with Agios Pharmaceuticals in the United States for the autoimmune disease candidate compound Sevydopylenib, KRW 34,041,650,000— the portion not subject to refund obligations— was recognized as revenue. The upfront payment and future milestones and royalties will be allocated in a 75% to 25% split between OscoTech and its subsidiary Genosco, respectively.


Milestone and royalty income from Lazertinib also contributed KRW 20 billion. This is approximately 1.9 times higher than the KRW 10.5 billion recorded in the first half of last year. The increase was due to a European commercialization milestone and higher royalties from expanded global sales.


OscoTech and Genosco are the original developers of Lazertinib and transferred the technology to Yuhan Corporation in 2015. Subsequently, Yuhan Corporation out-licensed it to Janssen Biotech, from which it now receives milestones and royalties based on commercialization.


Despite the improvement in results, the company increased its research and development investment. In the first half of the year, R&D expenses were KRW 15,041,680,000, a 20.6% increase from KRW 12,469,350,000 in the same period last year.


OscoTech plans to leverage its secured resources to advance the Phase 1 clinical trial for the anti-resistant cancer candidate OCT-598 and further develop subsequent pipeline candidates such as the renal fibrosis therapeutic OCT-648. The company is also working to expand its core research personnel.



Lee Sanghyun, CEO of OscoTech, stated, "Based on our secured resources and liquidity, we will thoroughly push forward with our key R&D projects, enhance the efficiency of R&D expenditure, and strengthen internal management by more rigorously allocating internal resources, thereby reinforcing our management fundamentals."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing